An update on the management of young-onset Parkinson’s disease

References

• GolbeLIYoung-onset Parkinson’s disease: a clinical reviewNeurology19914121681731992358
   PubMed Web of Science ®Google Scholar
• MartillaRJRineUKEpidemiology of Parkinson’s disease in FinlandActa Neurol Scand1976532811021266565
   PubMed Web of Science ®Google Scholar
• SchragABen ShlomoYQuinnNPCross sectional prevalence survey of idiopathic Parkinson’s disease and Parkinsonism in LondonBMJ20003217252212210875828
   PubMed Web of Science ®Google Scholar
• MuthaneUBSwamyHSSatishchandraPSubhashMNRaoSSubbakrishnaDEarly onset Parkinson’s disease: are juvenile- and young-onset different?Mov Disord1994955395447527483
   PubMed Web of Science ®Google Scholar
• StephenKVan Den EedenCTannerMIncidence of Parkinson’s Disease: variation by age, gender, and race/ethnicityAm J Epidemiol2003157111015102212777365
   PubMed Web of Science ®Google Scholar
• QuinnNCritchleyPMarsdenCDYoung onset Parkinson’s diseaseMov Disord19872273913504266
   PubMedGoogle Scholar
• GelbDJOliverEGilmanSDiagnostic Criteria for Parkinson DiseaseArch Neurol199956133399923759
   PubMed Web of Science ®Google Scholar
• CalneDBSnowBJLeeCCriteria for diagnosing Parkinson’s DiseaseAnn Neurol199232Suppl125127
   PubMed Web of Science ®Google Scholar
• GibbWRGLeesAJA comparison of clinical and pathological features of young- and old-onset Parkinson’s diseaseNeurology1988389140214063412587
   PubMed Web of Science ®Google Scholar
• JankovicJMotor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestationsMov Disord20052011111615455447
   PubMed Web of Science ®Google Scholar
• FriedmanAOld-onset Parkinson’s disease compared with young-onset disease: clinical differences and similaritiesActa Neurol Scand19948942582618042442
   PubMed Web of Science ®Google Scholar
• SpicaVPekmezovićTSvetelMKostićVSPrevalence of non-motor symptoms in young-onset versus late-onset Parkinson’s diseaseJ Neurol2013260113113722820720
   PubMed Web of Science ®Google Scholar
• PantelatosAFornadiFClinical features and medical treatment of Parkinson’s disease in patient groups selected in accordance with age at onsetAdv Neurol1993606906978420212
   PubMedGoogle Scholar
• KuSGlassGAAge of Parkinson’s disease onset as a predictor for the development of dyskinesiaMov Disord20102591177118220310028
   PubMed Web of Science ®Google Scholar
• RascolOLevodopa-induced peak-dose dyskinesias in patients with Parkinson’s disease: a clinical pharmacologic approachMov Disord1999141193210493400
   PubMed Web of Science ®Google Scholar
• JankovicJNourFRespiratory dyskinesia in Parkinson’s diseaseNeurology1986362303304
   Web of Science ®Google Scholar
• RiceJEAnticRThompsonPDDisordered respiration as a levodopa-induced dyskinesia in Parkinson’s diseaseMov Disord200217352452712112201
   PubMed Web of Science ®Google Scholar
• SchragABen-ShlomoYBrownRMarsdenCDQuinnNYoung-onset Parkinson’s disease revisited – clinical features, natural history, and mortalityMov Disord19981368858949827611
   PubMed Web of Science ®Google Scholar
• GoetzCGTannerCMStebbinsGTBuchmanASRisk factors for progression in Parkinson’s diseaseNeurology19883812184118443194061
   PubMed Web of Science ®Google Scholar
• HietanenMTeravainenHThe effect of aging and onset on neuropsychological performance in Parkinson’s diseaseJ Neurol Neurosurg Psychiatry198851244249
   Web of Science ®Google Scholar
• LiebermanADziatolowskiMKupersmithMDementia in Parkinson’s diseaseAnn Neurol19796355359554525
   PubMed Web of Science ®Google Scholar
• KnipeMDWickremaratchiMMWyatt-HainesEMorrisHRBen-ShlomoYQuality of life in young- compared with late-onset Parkinson’s diseaseMov Disord201126112011201821574185
   PubMed Web of Science ®Google Scholar
• Ben-ShlomoYMarmotMGSurvival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology?J Neurol Neurosurg Psychiatry19955832932997897409
   PubMed Web of Science ®Google Scholar
• BennettDABeckettLAMurrayAMPrevalence of parkinsonian signs and associated mortality in a community population of older peopleN Engl J Med1996334271768531961
   PubMed Web of Science ®Google Scholar
• De la Fuente-FernándezRRole of DaTSCAN and clinical diagnosis in Parkinson diseaseNeurology2012781069670122323748
   PubMed Web of Science ®Google Scholar
• BharuchaKJFriedmanJKVincentASRossEDLower serum ceruloplasmin levels correlate with younger age of onset in Parkinson’s diseaseJ Neurol2008255121957196219159062
   PubMed Web of Science ®Google Scholar
• HochstrasserHBauerPWalterUCeruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson diseaseNeurology2004631912191715557511
   PubMed Web of Science ®Google Scholar
• BergDHochstrasserHSchweitzerKJRiessODisturbance of iron metabolism in Parkinson’s disease – ultrasonography as a biomarkerNeurotox Res20069111316464747
   PubMed Web of Science ®Google Scholar
• GotzMEDoubleKGerlachMYoudimMBRiedererPThe relevance of iron in the pathogenesis of Parkinson’s diseaseAnn N Y Acad Sci2004101219320815105267
   PubMed Web of Science ®Google Scholar
• RisslingIStrauchKHöftCOertelWHMöllerJCHaplotype analysis of the engrailed-2 gene in young-onset Parkinson’s diseaseNeurodegenerative Dis200963102105
   Web of Science ®Google Scholar
• MacedoMGVerbaanDFangYGenotypic and phenotypic characteristics of Dutch patients with early onset Parkinson’s diseaseMov Disord200924219620318973254
   PubMed Web of Science ®Google Scholar
• ChoiJMWooMSMaHIAnalysis of PARK genes in a Korean cohort of early-onset Parkinson diseaseNeurogenetics20089426326918704525
   PubMed Web of Science ®Google Scholar
• GuoJFZhangXWNieLLMutation analysis of Parkin, PINK1 and DJ-1 genes in Chinese patients with sporadic early onset parkinsonismJ Neurol201025771170117520146068
   PubMed Web of Science ®Google Scholar
• Aguiar PdeCLessaPSGodeiroCJrGenetic and environmental findings in early-onset Parkinson’s disease Brazilian patientsMov Disord20082391228123318464276
   PubMed Web of Science ®Google Scholar
• LatourelleJCPankratzNDumitriuAGenomewide association study for onset age in Parkinson diseaseBMC Med Genet2009109819772629
   PubMed Web of Science ®Google Scholar
• PankratzNForoudTGenetics of Parkinson diseaseGenet Med200791280181118091429
   PubMed Web of Science ®Google Scholar
• KeyserRJLesageSBriceACarrJBardienSAssessing the prevalence of PINK1 genetic variants in South African patients diagnosed with early- and late-onset Parkinson’s diseaseBiochem Biophys Res Commun2010398112512920558144
   PubMed Web of Science ®Google Scholar
• ValenteEMAbou-SleimanPMCaputoVHereditary early-onset Parkinson’s disease caused by mutations in PINK1Science200430456741158116015087508
   PubMed Web of Science ®Google Scholar
• Abou-SleimanPMMuqitMMMcDonaldNQA heterozygous effect for PINK1 mutations in Parkinson’s disease?Ann Neurol200660441441916969854
   PubMed Web of Science ®Google Scholar
• NicholsWCPankratzNHernandezDGenetic screening for a single common LRRK2 mutation in familial Parkinson’s diseaseLancet2005365945741041215680455
   PubMed Web of Science ®Google Scholar
• LatourelleJCSunMLewMFThe Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson’s Disease: the GenePD studyBMC Med2008613218986508
   PubMed Web of Science ®Google Scholar
• GoldwurmSZiniMMarianiLEvaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson diseaseNeurology200768141141114317215492
   PubMed Web of Science ®Google Scholar
• TongYPisaniAMartellaGR1441C mutation in LRRK2 impairs dopaminergic neurotransmission in miceProc Natl Acad Sci U S A200910634146221462719667187
   PubMed Web of Science ®Google Scholar
• PolymeropoulosMHLavedanCLeroyEMutation in the alpha-synuclein gene identified in families with Parkinson’s diseaseScience19972765321204520479197268
   PubMed Web of Science ®Google Scholar
• LinXParisiadouLGuXLLeucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson’s-disease-related mutant alpha-synucleinNeuron200964680782720064389
   PubMed Web of Science ®Google Scholar
• Carballo-CarbajalIWeber-EndressSRovelliGLeucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathwayCell Signal201022582182720074637
   PubMed Web of Science ®Google Scholar
• NemaniVMLuWBergeVIncreased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosisNeuron2010651667920152114
   PubMed Web of Science ®Google Scholar
• PiccoliGCondliffeSBBauerMLRRK2 controls synaptic vesicle storage and mobilization within the recycling poolJ Neurosci20113162225223721307259
   PubMed Web of Science ®Google Scholar
• SiegelGJChauhanNBNeurotrophic factors in Alzheimer’s and Parkinson’s disease brainBrain Res Rev2000332–319922711011066
   PubMedGoogle Scholar
• StoesslJPotential therapeutic targets for Parkinson’s diseaseExpert Opin Ther Targets200812442543618348679
   PubMed Web of Science ®Google Scholar
• RossOASoto-OrtolazaAIHeckmanMGGenetic Epidemiology Of Parkinson’s Disease (GEO-PD) ConsortiumAssociation of LRRK2 exonic variants with susceptibility to Parkinson’s disease: a case-control studyLancet Neurol2011101089890821885347
   PubMed Web of Science ®Google Scholar
• SchapiraAHFuture directions in the treatment of Parkinson’s diseaseMov Disord20072217385391
   Web of Science ®Google Scholar
• RascolOBrooksDJKorczynADDevelopment of dyskinesias in a 5-year trial of ropinirole and L-dopaMov Disord200621111844185016958094
   PubMed Web of Science ®Google Scholar
• HollowayRGShoulsonIFahnSPramipexole vs levodopa as initial treatment for Parkinson disease a 4-year randomized controlled trialArch Neurol20046171044105315262734
   PubMedGoogle Scholar
• RascolOBrooksDJKorczynADDe DeynPPClarkeCELangAEA five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study GroupN Engl J Med2000342201484149110816186
   PubMed Web of Science ®Google Scholar
• OertelWHWoltersESampaioCPergolide versus levodopa monotherapy in early Parkinson’s disease patients: The PELMOPET studyMov Disord200621334335316211594
   PubMed Web of Science ®Google Scholar
• RinneUKBraccoFChouzaCEarly treatment of Parkinson’s disease with cabergoline delays the onset of motor complications – results of a double-blind levodopa controlled trialDrugs199855Suppl 123239483167
   PubMed Web of Science ®Google Scholar
• LeesAJKatzenschlagerRHeadJBen ShlomoYTen year follow up of three differentinitial treatments in de-novo PD: a randomized trialNeurology20015791687169411706112
   PubMed Web of Science ®Google Scholar
• HauserRARascolOKorczynADTen-year follow-up of Parkinson’s disease patients randomized to initial therapy with ropinirole or levodopaMov Disord200722162409241717894339
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group CALM Cohort InvestigatorsLong-term effect of initiating pramipexole vs levodopa in early Parkinson diseaseArch Neurol200966556357019433655
   PubMedGoogle Scholar
• KorczynADKeensJOldhamMMacraeSThe safety and efficacy of ropinirole as early therapy in elderly patients with Parkinson’s diseaseNeurology2008547 Suppl 3A90
   Google Scholar
• SchapiraAHVNeuroprotection and dopamine agonistsNeurology2002584 Suppl 191811781397
   PubMed Web of Science ®Google Scholar
• WhoneALWattsRLStoesslAJSlower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET studyAnn Neurol20035419310112838524
   PubMed Web of Science ®Google Scholar
• RavinaBMarekKEberlySDopamine transporter imaging is associated with long-term outcomes in Parkinson’s diseaseMov Disord201227111392139722976926
   PubMed Web of Science ®Google Scholar
• VoonVHassanKZurowskiMProspective prevalence of pathologic gambling and medication association in Parkinson diseaseNeurology20066611750175216769956
   PubMed Web of Science ®Google Scholar
• WeintraubDSiderowfADPotenzaMNAssociation of dopamine agonist use with impulse control disorders in Parkinson diseaseArch Neurol200663796997316831966
   PubMedGoogle Scholar
• VoonVHassanKZurowskiMPrevalence of repetitive and reward-seeking behaviors in Parkinson diseaseNeurology20066771254125716957130
   PubMed Web of Science ®Google Scholar
• FerreiraJJKatzenschlagerRBloemBRSummary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s diseaseEur J Neurol201320151523279439
   PubMed Web of Science ®Google Scholar
• FoxSHKatzenschlagerRLimSYThe Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the motor symptoms of Parkinson’s diseaseMov Disord201126Suppl 324121322013
   PubMed Web of Science ®Google Scholar
• IvesNJStoweRLMarroJMonoamine oxidase type B inhibitors in early Parkinson’s disease: meta-analysis of 17 randomised trials involving 3525 patientsBMJ2004329746659315310558
   PubMed Web of Science ®Google Scholar
• SternMParkinson Study GroupA controlled trial of rasagiline in Parkinson’s disease patients with levodopa-related motor fluctuations (PRESTO Study) [abstract]Ann Neurol20035427
   Web of Science ®Google Scholar
• Management of Parkinson’s disease: an evidence-based reviewMov Disord200217160166
   Google Scholar
• ThomasAIaconoDLucianoALArmellinoKDi IorioAOnofrjMDuration of amantadine benefit on dyskinesia of severe Parkinson’s diseaseJ Neurol Neurosurg Psychiatry200475114114314707325
   PubMed Web of Science ®Google Scholar
• EliaAEDollenzCSoliveriaPAlbaneseAMotor features and response to oral levodopa in patients with Parkinson’s disease under continuous dopaminergic infusion or deep brain stimulationEur J Neurol2012191768321645174
   PubMed Web of Science ®Google Scholar
• PfeifferRFPotential of transdermal drug delivery in Parkinson’s diseaseDrugs Aging20021956157012207550
   PubMed Web of Science ®Google Scholar
• AhlskogJEBeating a dead horse – dopamine and Parkinson diseaseNeurology200769171701171117954785
   PubMed Web of Science ®Google Scholar
• HonigHAntoniniAMartinez-MartinPIntrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of lifeMov Disord200924101468147419425079
   PubMed Web of Science ®Google Scholar
• DeuschlGSchade-BrittingerCKrackPA randomized trial of deep-brain stimulation for Parkinson’s diseaseN Engl J Med2006355989690816943402
   PubMed Web of Science ®Google Scholar
• YuHNeimatJSThe treatment of movement disorders by deep brain stimulationNeurotherapeutics200851263618164481
   PubMed Web of Science ®Google Scholar
• BenabidALPollakPGaoDChronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disordersJ Neurosurg19968422032148592222
   PubMed Web of Science ®Google Scholar
• Kleiner-FismanGHerzogJFismanDNSubthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomesMov Disord200621Suppl 14290304
   PubMed Web of Science ®Google Scholar
• HamaniCRichterESchwalbJMLozanAMBilateral subthalamic nucleus stimulation for Parkinson’s disease: a systematic review of the clinical literatureNeurosurgery20055661313132115918948
   PubMed Web of Science ®Google Scholar
• SchüpbachWMMaltêteDHouetoJLNeurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trialNeurology200764267271
   Web of Science ®Google Scholar
• DerostPPOuchchaneLMorandDIs DBS-STN appropriate to treat severe Parkinson disease in an elderly population?Neurology200768171345135517452578
   PubMed Web of Science ®Google Scholar
• OdekerkenVJvan LaarTStaalMJSubthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson’s disease (NSTAPS study): a randomised controlled trialLancet Neurol2013121374423168021
   PubMed Web of Science ®Google Scholar
• OkunMSFooteKDSubthalamic nucleus vs globus pallidus interna deep brain stimulation, the rematch: will pallidal deep brain stimulation make a triumphant return?Arch Neurol200562453353615824249
   PubMedGoogle Scholar
• AndersonVCBurchielKJHogarthPFavreJHammerstadJPPallidal vs subthalamic nucleus deep brain stimulation in Parkinson diseaseArch Neurol200562455456015824252
   PubMed Web of Science ®Google Scholar
• SchneebergerAMandlerMMattnerFSchmidtWVaccination for Parkinson’s diseaseParkinsonism Relat Disord201218Suppl 11113
   Web of Science ®Google Scholar
• MasliahERockensteinEAdameAEffects of alpha-synuclein immunization in a mouse model of Parkinson’s diseaseNeuron20051646 (6):857–868.
   Google Scholar
• GrossCRougierAGuehlDBoraudTJulienJBioulacBHigh-frequency stimulation of the globus pallidus internalis in Parkinson’s disease: a study of seven casesJ Neurosurg19978744914989322838
   PubMed Web of Science ®Google Scholar
• PahwaRWilkinsonSSmithDLyonsKMiyawakiEKollerWCHigh-frequency stimulation of the globus pallidus for the treatment of Parkinson’s diseaseNeurology19974912492539222199
   PubMed Web of Science ®Google Scholar
• KumarRLangAERodriguez-OrozMCDeep brain stimulation of the globus pallidus pars interna in advanced Parkinson’s diseaseNeurology20005512 Suppl 63439
   Web of Science ®Google Scholar
• VolkmannJAllertNVogesJSturmVSchnitzlerAFreundHJLong-term results of bilateral pallidal stimulation in Parkinson’s diseaseAnn Neurol200455687187515174022
   PubMed Web of Science ®Google Scholar
• Visser-VandewalleVvan der LindenCTemelYNiemanFCelikHBeulsELong-term motor effect of unilateral pallidal stimulation in 26 patients with advanced Parkinson diseaseJ Neurosurg200399470170714567606
   PubMed Web of Science ®Google Scholar
• CalneSMKumarAYoung onset Parkinson’s disease. Practical management of medical issuesParkinsonism Relat Disord200814213314217804273
   PubMed Web of Science ®Google Scholar
• HoehnMMYahrMDParkinsonism: onset, progression, and mortalityNeurology19671754274426067254
   PubMed Web of Science ®Google Scholar
• JankovicJMcDermottMCarterJVariable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study GroupNeurology19904010152915342215943
   PubMed Web of Science ®Google Scholar
• MerolaAZibettiMArtusiCASubthalamic nucleus deep brain stimulation outcome in young onset Parkinson’s disease: a role for age at disease onset?J Neurol Neurosurg Psychiatry201283325125722180646
   PubMed Web of Science ®Google Scholar
• BronsteinJMDeSallesADeLongMRStereotactic pallidotomy in the treatment of Parkinson’s Disease: an expert opinionArch Neurol19995691064106910488806
   PubMedGoogle Scholar
• MarsacLChauvetDLarratBMR-guided adaptive focusing of therapeutic ultrasound beams in the human headMed Phys20123921141114922320825
   PubMed Web of Science ®Google Scholar
• HelyMAFungVSCMorrisJGLTreatment of Parkinson’s DiseaseJ Clin Neurosci20007648449411029227
   PubMed Web of Science ®Google Scholar
• InSightecExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential Tremor Available from: http://clinicaltrials.gov/ct2/show/NCT01304758 NLM identifier: NCT01304758Accessed July 10, 2013
   Google Scholar
• HuangYHynynenKMR-guided focused ultrasound for brain ablation and blood–brain barrier disruptionMethods Mol Biol201171157959321279624
   PubMedGoogle Scholar
• JeanmonodDWernerBMorelATranscranial magnetic resonance imaging-guided focused ultrasound: noninvasive central lateral thalamotomy for chronic neuropathic painNeurosurg Focus20123211
   PubMed Web of Science ®Google Scholar
• EvansJRBarkerRANeurotrophic factors as a therapeutic target for Parkinson’s diseaseExpert Opin Ther Targets200812443744718348680
   PubMed Web of Science ®Google Scholar
• PoeweWMahlknechtPJankovicJEmerging therapies for Parkinson’s diseaseCurr Opin Neurol201225444845922772874
   PubMed Web of Science ®Google Scholar
• AstradssonACooperOVinuelaAIsacsonORecent advances in cell-based therapy for Parkinson diseaseNeurosurg Focus2008243–46
   Web of Science ®Google Scholar
• SantosCMNew agents promote neuroprotection in Parkinson’s disease modelsCNS Neurol Disord Drug Targets201211441041822483311
   PubMed Web of Science ®Google Scholar
• KirikDRosenbladCBjorklundAMandelRILong-term rAAV-mediated gene transfer of GDNF in the rat Parkinson’s model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal systemJ Neurosci200020124686470010844038
   PubMed Web of Science ®Google Scholar
• GasmiMHerzogCDBrandonEPStriatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson’s diseaseMol Ther2007151626817164776
   PubMed Web of Science ®Google Scholar
• FreedCRBreezeRERosenbergNLSurvival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson’s diseaseN Engl J Med199232722154915551435881
   PubMed Web of Science ®Google Scholar
• PicciniPBrooksDJBjörklundADopamine release from nigral transplants visualized in vivo in a Parkinson’s patientNat Neurosci19992121137114010570493
   PubMed Web of Science ®Google Scholar
• MendezISanchez-PernauteRCooperOCell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson’s diseaseBrain200512871498151015872020
   PubMed Web of Science ®Google Scholar
• MasliahERockensteinEManteMPassive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body diseasePLoS One201164193198
   Web of Science ®Google Scholar
• LeWittPARezaiARLeeheyMAAAV2-GAD gene therapy for advanced Parkinson’s disease: a double-blind, sham-surgery controlled, randomised trialLancet Neurol201110430913921419704
   PubMed Web of Science ®Google Scholar
• MarksWJJrBartusRTSiffertJGene delivery of AAV2-neurturin for Parkinson’s disease: a double-blind, randomised, controlled trialLancet Neurol20109121164117220970382
   PubMed Web of Science ®Google Scholar
• LinazasoroGCell therapy for Parkinson’s disease: only young onset patients allowed? Reflections about the results of recent clinical trials with cell therapy and the progression of Parkinson’s diseaseCell Transplant20061546347317121157
   PubMed Web of Science ®Google Scholar
• FarleyBGKoshlandGFTraining BIG to move faster: the application of the speed–amplitude relation as a rehabilitation strategy for people with Parkinson’s diseaseExp Brain Res2005167346246716283401
   PubMed Web of Science ®Google Scholar
• SchenkmanMDonovanJTsubotaJKlussMStebbinsPButlerRBManagement of individuals with Parkinson’s disease: rationale and case studiesPhys Ther198969119449552813522
   PubMed Web of Science ®Google Scholar
• SutooDAkiyamaKRegulation of brain function by exerciseNeurobiol Dis200313111412758062
   PubMed Web of Science ®Google Scholar
• GoodwinVARichardsSHTaylorRSTaylorAHCampbellJLThe effectiveness of exercise interventions for people with Parkinson’s disease: a systematic review and meta-analysisMov Disord200823563164018181210
   PubMed Web of Science ®Google Scholar
• LewisGNByblowWDWaltSEStride length regulation in Parkinson’s disease: the use of extrinsic visual cuesBrain2000123102077209011004125
   PubMed Web of Science ®Google Scholar